KR20090036151A - 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법 - Google Patents

신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법 Download PDF

Info

Publication number
KR20090036151A
KR20090036151A KR1020097006051A KR20097006051A KR20090036151A KR 20090036151 A KR20090036151 A KR 20090036151A KR 1020097006051 A KR1020097006051 A KR 1020097006051A KR 20097006051 A KR20097006051 A KR 20097006051A KR 20090036151 A KR20090036151 A KR 20090036151A
Authority
KR
South Korea
Prior art keywords
fgf23
leu
gly
arg
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097006051A
Other languages
English (en)
Korean (ko)
Inventor
마이클 이콘스
켄 화이트
팀 마티아스 스트롬
토마스 마이틴거
Original Assignee
인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션
루드비히-막시밀리안스-우니베르지타트 뮌헨 아브타일룽 메디치니쉐 게네티크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20090036151(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션, 루드비히-막시밀리안스-우니베르지타트 뮌헨 아브타일룽 메디치니쉐 게네티크 filed Critical 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션
Publication of KR20090036151A publication Critical patent/KR20090036151A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
KR1020097006051A 2000-07-19 2001-07-10 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법 Ceased KR20090036151A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21913700P 2000-07-19 2000-07-19
US60/219,137 2000-07-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020037000821A Division KR100924183B1 (ko) 2000-07-19 2003-01-18 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법

Publications (1)

Publication Number Publication Date
KR20090036151A true KR20090036151A (ko) 2009-04-13

Family

ID=22818027

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097006051A Ceased KR20090036151A (ko) 2000-07-19 2001-07-10 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
KR1020037000821A Expired - Lifetime KR100924183B1 (ko) 2000-07-19 2003-01-18 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020037000821A Expired - Lifetime KR100924183B1 (ko) 2000-07-19 2003-01-18 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법

Country Status (11)

Country Link
US (5) US7223563B2 (enExample)
EP (2) EP1303536B1 (enExample)
JP (2) JP2004504063A (enExample)
KR (2) KR20090036151A (enExample)
CN (1) CN1446227B (enExample)
AT (1) ATE461213T1 (enExample)
AU (2) AU2001273323B2 (enExample)
CA (1) CA2418215A1 (enExample)
DE (1) DE60141582D1 (enExample)
ES (1) ES2340662T3 (enExample)
WO (1) WO2002008271A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060160181A1 (en) * 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
EP1261638A2 (en) * 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
CN100387713C (zh) * 2000-08-11 2008-05-14 麒麟医药株式会社 调节磷酸代谢,钙代谢,钙化和维生素d代谢的多肽及其编码dna
US7226749B2 (en) 2000-12-05 2007-06-05 Zahradnik Richard J Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US6838264B2 (en) 2000-12-05 2005-01-04 Immutopics, Inc. Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
KR20030074678A (ko) * 2000-12-26 2003-09-19 추가이 세이야쿠 가부시키가이샤 혈중 인농도를 저하시키는 인간 ｆｇｆ２３ 단백질 변이체
CN1602355A (zh) * 2001-04-26 2005-03-30 杰诺瓦有限公司 与人成纤维细胞生长因子有关的组合物
CA2471656C (en) 2001-12-28 2012-07-31 Kirin Beer Kabushiki Kaisha Antibody against fibroblast growth factor-23
US7094551B2 (en) 2002-09-17 2006-08-22 Zahradnik Richard J Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JP5118851B2 (ja) * 2003-11-07 2013-01-16 ノバルティス アーゲー 線維芽細胞増殖因子フラグメントの使用
WO2005108607A1 (en) * 2004-05-09 2005-11-17 Technion Research & Development Foundation Ltd. Compositions and methods for treating disorders associated with abnormal phosphate metabolism
IL161886A0 (en) * 2004-05-09 2005-11-20 Technion Res & Dev Foundation Development of inducers of udp-n-acetyl-alphad-galactosamine: polypeptide n-acetylgalactosami-nyltransferase 3(ppgantase
BRPI0612974A2 (pt) * 2005-04-18 2010-12-14 Clearplay Inc produto de programa de computador, sinal de dados de computador incorporado em uma mÍdia de transmissço, mÉtodo para associar uma apresentaÇço de multimÍdia com informaÇÕes de filtro de conteédo e reprodutor de multimÍdia
KR100760525B1 (ko) * 2006-04-13 2007-10-04 김재만 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법
US8012694B2 (en) 2006-09-14 2011-09-06 Immutopics, Inc. Assay for the detection of phosphorylated PTH
WO2008089936A1 (en) * 2007-01-22 2008-07-31 Medizinische Universität Innsbruck Novel markers for chronic kidney disease
US7883705B2 (en) * 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
MX2010011959A (es) * 2008-04-29 2010-11-30 Novartis Ag Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos.
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
JP5865838B2 (ja) 2010-08-31 2016-02-17 協和メデックス株式会社 線維芽細胞増殖因子−２３の測定方法及び測定試薬
WO2012055096A1 (zh) * 2010-10-27 2012-05-03 温州医学院生物与天然药物开发中心有限公司 抗fgf-23抗体的制备方法及用途
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
WO2013006486A2 (en) 2011-07-01 2013-01-10 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
IL292303A (en) 2012-12-27 2022-06-01 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostatsis and treatment of bile acid disorders and disease
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2015040497A2 (en) * 2013-09-20 2015-03-26 Lonza Ltd Methods for nuclear reprogramming of cells
SG11201602870YA (en) 2013-10-28 2016-05-30 Ngm Biopharmaceuticals Inc Cancer models and associated methods
PL3097122T3 (pl) 2014-01-24 2020-10-19 Ngm Biopharmaceuticals, Inc. Przeciwciała wiążące domenę 2 beta klotho oraz sposoby ich stosowania
JP2017517272A (ja) 2014-03-28 2017-06-29 ニューヨーク・ユニバーシティ Ｆｇｆ２３融合タンパク質
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3845245B1 (en) 2014-06-09 2025-06-25 Ultragenyx Pharmaceutical Inc. The effective and efficient control of serum phosphate for optimal bone formation
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
EP3227319B1 (en) 2014-12-04 2019-11-27 Novartis AG Methods and compositions using klotho variant polypeptides
CN105699664A (zh) * 2015-04-13 2016-06-22 陈柏龄 Fgf23检测试剂盒及其制备方法
WO2016210350A1 (en) * 2015-06-25 2016-12-29 Amyris, Inc. Maltose dependent degrons, maltose-responsive promoters, stabilization constructs, and their use in production of non-catabolic compounds
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
AU2016353988B2 (en) 2015-11-09 2019-09-26 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
WO2018039557A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
CA3058306A1 (en) * 2017-03-28 2018-10-04 Ajinomoto Co., Inc. Additive for undifferentiation maintaining medium
EP3633373B1 (en) 2017-05-31 2025-02-19 Hitachi Chemical Diagnostics Systems Co., Ltd. Measurement method for fibroblast growth factor 23, measurement reagent, and measurement kit
WO2020047475A1 (en) * 2018-08-30 2020-03-05 The Uab Research Foundation Drug screening for fgf23-fgfr4 inhibitors
JP2022527790A (ja) * 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子
KR20210153069A (ko) * 2019-04-19 2021-12-16 제네똥 섬유아세포 성장 인자 23 관련 저인산혈증성 질환의 유전자 요법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
EP0708658A4 (en) 1993-04-16 1997-05-21 Wistar Inst RECOMBINANT CYTOMEGALOVIRUS VACCINE
US5693775A (en) * 1995-05-12 1997-12-02 The Johns Hopkins University School Of Medicine Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use
AU3774300A (en) 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1666494A1 (en) * 1999-12-01 2006-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2382165A1 (en) 1999-12-08 2001-06-14 Genset S.A. Full-length human cdnas encoding potentially secreted proteins
AU2759201A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf12
WO2001060850A1 (en) 2000-02-14 2001-08-23 Smithkline Beecham Corporation Novel compounds
EP1257645A2 (en) * 2000-02-15 2002-11-20 Amgen Inc. Fibroblast growth factor-23 molecules and uses thereof
EP1261638A2 (en) * 2000-03-08 2002-12-04 Chiron Corporation Human fgf-23 gene and gene expression products
WO2002076467A1 (en) * 2001-03-22 2002-10-03 Genzyme Corporation Compositions and methods to regulate bone and mineral metabolism

Also Published As

Publication number Publication date
US8586317B2 (en) 2013-11-19
WO2002008271A1 (en) 2002-01-31
KR100924183B1 (ko) 2009-10-28
AU2001273323B2 (en) 2005-11-10
JP2008194039A (ja) 2008-08-28
US7314618B2 (en) 2008-01-01
US20020156001A1 (en) 2002-10-24
CA2418215A1 (en) 2002-01-31
EP1303536A1 (en) 2003-04-23
US20080241946A1 (en) 2008-10-02
US20120064544A1 (en) 2012-03-15
US7223563B2 (en) 2007-05-29
US20030181379A1 (en) 2003-09-25
DE60141582D1 (de) 2010-04-29
AU7332301A (en) 2002-02-05
ATE461213T1 (de) 2010-04-15
JP2004504063A (ja) 2004-02-12
US7745406B2 (en) 2010-06-29
EP1303536A4 (en) 2005-01-05
US20090311792A1 (en) 2009-12-17
CN1446227A (zh) 2003-10-01
CN1446227B (zh) 2011-10-05
EP1303536B1 (en) 2010-03-17
US7947810B2 (en) 2011-05-24
ES2340662T3 (es) 2010-06-08
KR20030029111A (ko) 2003-04-11
EP2184296A1 (en) 2010-05-12

Similar Documents

Publication Publication Date Title
KR100924183B1 (ko) 신규 섬유아세포 성장 인자 (ｆｇｆ23) 및 그의 이용 방법
AU2001273323A1 (en) Novel fibroblast growth factor (FGF23) and methods for use
PT2045322E (pt) Musculatura dupla em mamíferos
HU227703B1 (en) Mammalian cytokine-like polypeptide-10
SK7012003A3 (en) Fibroblast growth factors
Glowacki et al. Structure, chromosomal localization, and expression of the gene for mouse ecto-mono (ADP-ribosyl) transferase ART5
US6630325B1 (en) Compositions, methods and kits relating to remodel
US9049849B2 (en) Screening methods for compounds useful for treating pancreatic dysfunction
US20050049212A1 (en) Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis
WO1997038004A1 (en) Gene family associated with neurosensory defects
US20040242515A1 (en) Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy home-ostasis
JP2004514404A (ja) 血管形成関連タンパク質及びこれをコードする核酸
US20060241035A1 (en) Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome
US6537554B1 (en) Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20030125296A1 (en) Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
US20060168667A1 (en) Minibrain homologous proteins involved in the regulation of energy homeostasis
JP2003052388A (ja) 結腸特異的遺伝子およびタンパク質
JP2003000246A (ja) 松果腺特異的遺伝子−１

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20090324

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090423

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20091109

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20100630

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20091109

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I